MultiCell Technologies Inc. (OTCQB: MCET) stock volume soared Mar. 3, with 41,190,256 shares changing hands, significantly higher than its three-month average volume of 30,444,778 shares.
What is fueling the uptick in volume is anybody’s guess because the Woonsocket, R.IO.-based a biopharmaceutical company hasn’t issued a press release since Jan. 15 when it announced that it had filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death.
Translation: Cancer-killing biotechnology
Apply for Patent for Tumor-Fighting Technology
Here is an excerpt from the release, which unless you got straight As in biology and science, is difficult to comprehend:
“This patent application describes a novel class of very small noncoding double stranded RNA molecules (VSRNAs) which interfere with the basic homeostatic cellular processes in tumor cells. VSRNAs are of molecular size less than 10 bps, yet are surprisingly capable in their ability to affect the metabolism, viability and proliferative rate of tumor cells consistent with a mechanism of action that bypasses completely, or in part, the canonical known pathways and steps of RNA recognition and RNA interference.
This patent application describes a novel class of very small noncoding double stranded RNA molecules (VSRNAs) which interfere with the basic homeostatic cellular processes in tumor cells. VSRNAs are of molecular size less than 10 bps, yet are surprisingly capable in their ability to affect the metabolism, viability and proliferative rate of tumor cells consistent with a mechanism of action that bypasses completely, or in part, the canonical known pathways and steps of RNA recognition and RNA interference.
In contrast to other species of RNAs, VSRNAs can induce cell death through pyroptosis; a specific biological process that also involves pro-inflammatory cytokine production. Pyroptosis results from the capability of VSRNAs to suppress or modify the amount of mRNA expressing various endogenous genes linked to the metabolism, proliferation and viability of cells, thus inducing a state of cellular stress that results in deployment of mediators of innate immunity. VSRNAs described in this Application exert a preferential biological activity on certain tumor cells while showing no effect on normal, non-transformed cells.
Since cancer cells are highly metabolically active, they are more reliant on key housekeeping molecules for survival as opposed to normal cells. Through mobilization of stress pathways and non-canonical RNA sensors, VSRNAs have demonstrated the capability of activating the NF-kB pathway and Ca2+ release, resulting in (1) secretion of pre-formed cytokines stored in cell vesicles, and (2) de novo synthesis of cytokines and chemokines. VSRNAs can be formulated, attached or integrated within delivery vehicles that target or express selectively their payload in desired cell types resulting in both immediate and long-term therapeutic effects against cancer. “
No Update on Patent’s Status
Since this release, the company has not given an update on how the patent process is going.
Dated Financial
The latest financial filing made by MultiCell Technologies is Nov. 30, 2012, which reported that the company lost about $1.5 million.
On Mar. 3, MCET’s share price closed at 0.0008 cents, unchanged from its closing price the previous day.
Find out what could be the best investor’s move when it comes to MCET by getting the complete report here, or by cutting and pasting the following link in your Web browser:
http://www.sixfigurestockpicks.com
Presentation At Analyst Forum
Meanwhile, OncoSec Medical Inc. (OTCQB: ONCS), an emerging drug-medical device company, is not making much news these days.
It’s latest PR announcement is that it President and CEO Punit Dhillon will make a presentation at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m.
Its stock volume is a little below average, with only 3,037,401 shares changing hands, compared with its three-month average of 3,459,811 shares.
On Mar. 3, ONCS’s share price closed at 72 cents, up 3 cents from its closing price of 69 cents the previous day.
Find out what could be the best investor’s move when it comes to ONCS by getting the complete report here, or by cutting and pasting the following link in your Web browser:
http://www.sixfigurestockpicks.com
ABOUT US:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.sixfigurestockpicks.com
Disclosure
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.